Research Interests
I am interested in tumor immunology and developmental immunotherapeutics in gastrointestinal malignancies including gastric cancer, colorectal adenocarcinoma, pancreatic adenocarcinoma, cholangiocarcinoma, esophageal cancers, and hepatocellular carcinoma. My research focuses on metastatic mechanisms and how they influence tumor immune evasion during disease progression, particularly antigen presenting cells such as dendritic cells.
Selected Grants
A Phase1b/2, multicenter, randomized, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2025 - 2030A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator?s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression (2138-CL-0102)
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2025 - 2030A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal
Clinical TrialPrincipal Investigator · Awarded by Legend Biotech USA, Inc. · 2025 - 2030Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)
Clinical TrialPrincipal Investigator · Awarded by Agenus, Inc. · 2024 - 2029A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Xilio Development Inc. · 2024 - 2029A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2024 - 2029Botensilimab and Balstilimab Optimization in Colorectal cancer (BBOpCo)
Clinical TrialPrincipal Investigator · Awarded by Gateway for Cancer Research · 2024 - 2027Overcoming Anti-PD-1 Resistance in Melanoma by Targeting Immunologic Mediators of the Gli2 Pathway
ResearchCollaborator · Awarded by The Melanoma Research Foundation · 2022 - 2025A Phase 1/1b Study of ASP2074 in Participants with Metastatic or Locally Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2024 - 2025The NLRP3-HSP70 Axis and Immunotherapy Resistance in Gastric Cancer
ResearchLaboratory Assistant · Awarded by American Association for Cancer Research · 2023 - 2024Expanded access use of MRTX849 for the treatment of patients with advanced solid tumors with a KRAS G12C mutation
Clinical TrialPrincipal Investigator · Awarded by Mirati Therapeutics, Inc. · 2022 - 2024Investigating the Role of EMT-mediated Dendritic Cell Tolerization in Checkpoint Inhibitor Resistance
ResearchPI-Fellow · Awarded by Damon Runyon Cancer Research Foundation · 2018 - 2022Investigating Oncogenic Signaling Pathways that Drive Wnt Ligand-mediated Immune Tolerance in Melanoma
ResearchPI-Fellow · Awarded by Conquer Cancer Foundation · 2017 - 2018External Relationships
- GLG Consultants
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.